We are reiterating our Buy rating and $22.50 price target for Betterware de Mexico, slightly tweaking our 3Q25 projection and updating our USD projections for actual 3Q FX rates with the company announcing results after the close Thursday. We believe Betterware remains highly focused
on overall returns for the namesake division, while JAFRA remains in a full market share expansion mode. As such, we believe management will remain upbeat on prospects for 2025 and beyond and the potential for gains from higher margins (and lower overall inventory levels) to fund further
growth (including new country expansion) and continue to reduce overall debt levels. With BWMX continuing to register a dividend yield of almost 9% and a valuation under 6X our 2026 EPS, we believe the risk/reward in the name remains compelling, and we reiterate our Buy rating and $22.50
price target for BWMX

16 Oct 2025
BWMX: 3Q Preview: Focused on Higher Returns; Reiterate Buy, $22.50 PT

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
BWMX: 3Q Preview: Focused on Higher Returns; Reiterate Buy, $22.50 PT
Medifast (MED:NYSE), 0 | Medifast, Inc. (MED:NYS), 0 | Betterware de Mexico, S.A.P.I. de C.V. (BWMX:NYS), 0 | DD3 Acquisition Corp (DDMX:NYSE), 0 | Nu Skin Enterprises (NUS:NYSE), 0 | Nu Skin Enterprises, Inc. Class A (NUS:NYS), 0
- Published:
16 Oct 2025 -
Author:
Eric Beder -
Pages:
5 -
We are reiterating our Buy rating and $22.50 price target for Betterware de Mexico, slightly tweaking our 3Q25 projection and updating our USD projections for actual 3Q FX rates with the company announcing results after the close Thursday. We believe Betterware remains highly focused
on overall returns for the namesake division, while JAFRA remains in a full market share expansion mode. As such, we believe management will remain upbeat on prospects for 2025 and beyond and the potential for gains from higher margins (and lower overall inventory levels) to fund further
growth (including new country expansion) and continue to reduce overall debt levels. With BWMX continuing to register a dividend yield of almost 9% and a valuation under 6X our 2026 EPS, we believe the risk/reward in the name remains compelling, and we reiterate our Buy rating and $22.50
price target for BWMX